JP2020536121A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536121A5 JP2020536121A5 JP2020539153A JP2020539153A JP2020536121A5 JP 2020536121 A5 JP2020536121 A5 JP 2020536121A5 JP 2020539153 A JP2020539153 A JP 2020539153A JP 2020539153 A JP2020539153 A JP 2020539153A JP 2020536121 A5 JP2020536121 A5 JP 2020536121A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- imeglimin
- day
- administered
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 22
- GFICWFZTBXUVIG-SCSAIBSYSA-N imeglimin Chemical compound C[C@H]1NC(N(C)C)=NC(N)=N1 GFICWFZTBXUVIG-SCSAIBSYSA-N 0.000 claims 12
- 229950005411 imeglimin Drugs 0.000 claims 12
- 230000037396 body weight Effects 0.000 claims 8
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 3
- -1 DPP-4 inhibitor Proteins 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 108091006277 SLC5A1 Proteins 0.000 claims 1
- 108091006269 SLC5A2 Proteins 0.000 claims 1
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 claims 1
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 claims 1
- 102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 claims 1
- 102000058081 Sodium-Glucose Transporter 2 Human genes 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 229940127003 anti-diabetic drug Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 208000029077 monogenic diabetes Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762566668P | 2017-10-02 | 2017-10-02 | |
| US62/566,668 | 2017-10-02 | ||
| PCT/IB2018/057648 WO2019069230A1 (en) | 2017-10-02 | 2018-10-02 | METHODS OF TREATING CARDIAC INSUFFICIENCY WITH PRESERVED EJECTION FRACTION |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020536121A JP2020536121A (ja) | 2020-12-10 |
| JP2020536121A5 true JP2020536121A5 (OSRAM) | 2021-12-02 |
Family
ID=63963334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020539153A Pending JP2020536121A (ja) | 2017-10-02 | 2018-10-02 | 駆出率が保持された心不全を治療する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11617754B2 (OSRAM) |
| EP (1) | EP3691650A1 (OSRAM) |
| JP (1) | JP2020536121A (OSRAM) |
| KR (1) | KR20200102982A (OSRAM) |
| CN (1) | CN111163782A (OSRAM) |
| BR (1) | BR112020006472A2 (OSRAM) |
| CA (1) | CA3078163A1 (OSRAM) |
| IL (1) | IL273723A (OSRAM) |
| MX (1) | MX2020003243A (OSRAM) |
| TW (1) | TW201924689A (OSRAM) |
| WO (1) | WO2019069230A1 (OSRAM) |
| ZA (1) | ZA202002292B (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020006472A2 (pt) | 2017-10-02 | 2020-10-06 | Poxel | método para tratamento ou prevenção de insuficiência cardíaca com fração de ejeção preservada (icfep) |
| CN111918655B (zh) | 2018-06-06 | 2024-05-31 | 博希尔公司 | 治疗患有慢性肾脏疾病的糖尿病受试者的方法 |
| KR20210003786A (ko) | 2018-06-14 | 2021-01-12 | 폭셀 | 당뇨병의 치료에서 사용하기 위한 트리아진 유도체를 포함하는 필름 코팅정 |
| CN115770062B (zh) * | 2021-09-07 | 2025-10-10 | 深圳迈瑞生物医疗电子股份有限公司 | 一种超声波数据的处理方法、成像装置 |
| CN116440075B (zh) * | 2023-06-01 | 2025-05-06 | 苏州中化药品工业有限公司 | 一种干混悬剂及其制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2804113B1 (fr) | 2000-01-26 | 2004-06-18 | Lipha | Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique |
| FR2853650B1 (fr) | 2003-04-10 | 2006-07-07 | Merck Sante Sas | Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance |
| FR2896161B1 (fr) | 2006-01-13 | 2008-04-04 | Merck Sante Soc Par Actions Si | Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique. |
| FR2896157B1 (fr) | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline. |
| FR2896159B1 (fr) | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline. |
| DE102008007314A1 (de) | 2008-02-02 | 2009-08-06 | Merck Patent Gmbh | Verfahren zur Herstellung von 3,6-Dihydro-1,3,5-triazinderivaten |
| SI2300444T1 (sl) | 2008-05-23 | 2016-10-28 | Poxel Sas | Proces za sintezo derivatov 3,6-dihidro-1,3,5-triazina |
| ES2569105T3 (es) | 2008-07-29 | 2016-05-06 | Poxel | Procedimiento para aislar componentes enantiómeros a partir de mezclas de enantiómeros por cristalización controlada por tamaño de partícula |
| AU2009326965A1 (en) | 2008-12-12 | 2011-06-23 | Poxel | Tetrahydrotriazine compounds for treating diseases associated with AMPK activity |
| EA021395B1 (ru) | 2008-12-12 | 2015-06-30 | Поксель Сас | Комбинация инсулина с триазиновыми производными и их применение для лечения диабета |
| US8742102B2 (en) | 2009-03-26 | 2014-06-03 | Poxel | Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization |
| FR2948027A1 (fr) | 2009-07-17 | 2011-01-21 | Merck Sante Sas | Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion |
| EP2579879B1 (en) | 2010-06-09 | 2016-03-23 | Poxel | Triazine derivatives for delaying the onset of type 1 diabetes |
| TWI436768B (zh) | 2010-06-09 | 2014-05-11 | Poxel | 第２型糖尿病之治療 |
| CN103228635B (zh) | 2010-12-01 | 2016-03-30 | 珀科赛尔 | 利用酒石酸分离三嗪衍生物对映异构体 |
| US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
| WO2014160524A1 (en) * | 2013-03-14 | 2014-10-02 | The Trustees Of The University Of Pennsylvania | Cardio- metabolic and cascular effects of glp-1 metabolites |
| CA2812519A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| EP3110449B1 (en) * | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| EP3217987A4 (en) | 2014-11-10 | 2018-06-20 | Merck Sharp & Dohme Corp. | Sglt-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease |
| MA43709A (fr) * | 2016-03-16 | 2018-11-28 | Boehringer Ingelheim Int | Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations |
| BR112020006472A2 (pt) | 2017-10-02 | 2020-10-06 | Poxel | método para tratamento ou prevenção de insuficiência cardíaca com fração de ejeção preservada (icfep) |
| CN111918655B (zh) | 2018-06-06 | 2024-05-31 | 博希尔公司 | 治疗患有慢性肾脏疾病的糖尿病受试者的方法 |
-
2018
- 2018-10-02 BR BR112020006472-6A patent/BR112020006472A2/pt not_active IP Right Cessation
- 2018-10-02 CN CN201880063705.4A patent/CN111163782A/zh active Pending
- 2018-10-02 EP EP18792513.6A patent/EP3691650A1/en not_active Withdrawn
- 2018-10-02 US US16/652,911 patent/US11617754B2/en active Active
- 2018-10-02 KR KR1020207011597A patent/KR20200102982A/ko not_active Ceased
- 2018-10-02 MX MX2020003243A patent/MX2020003243A/es unknown
- 2018-10-02 TW TW107134796A patent/TW201924689A/zh unknown
- 2018-10-02 JP JP2020539153A patent/JP2020536121A/ja active Pending
- 2018-10-02 CA CA3078163A patent/CA3078163A1/en active Pending
- 2018-10-02 WO PCT/IB2018/057648 patent/WO2019069230A1/en not_active Ceased
-
2020
- 2020-03-31 IL IL273723A patent/IL273723A/en unknown
- 2020-05-04 ZA ZA2020/02292A patent/ZA202002292B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536121A5 (OSRAM) | ||
| JP2020033360A5 (OSRAM) | ||
| JP6676108B2 (ja) | ２型糖尿病の処置のためのリキシセナチド及びメトホルミン | |
| IL274943B2 (en) | Combination of a 4-pyrimidinsulfamide derivative with an SGLT-2 inhibitor for the treatment of endothelin-related diseases | |
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| EP2523557B1 (en) | Methods of providing weight loss therapy in patients with major depression | |
| JP2016516016A5 (OSRAM) | ||
| NZ745778A (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| ES3009607T3 (en) | Nk-1 antagonist compositions and methods for use in treating depression | |
| JP5757544B2 (ja) | 癌治療に用いられるベムラフェニブとインターフェロンを含む併用療法 | |
| JP2018509419A5 (OSRAM) | ||
| JP2016505050A5 (OSRAM) | ||
| JP2005512946A5 (OSRAM) | ||
| US20190388370A1 (en) | Treatment of symptoms associated with female gastroparesis | |
| JP2024010018A (ja) | うつ病を治療するための組成物および方法 | |
| WO2013028882A1 (en) | Treatment of symptoms associated with female gastroparesis | |
| JP2020500930A5 (OSRAM) | ||
| PH12019502767A1 (en) | Oral pharmaceutical formulations of remogliflozin | |
| JP2022540198A (ja) | 組合せ | |
| Forner et al. | Pharmacotherapy for the management of overweight and obesity | |
| CN116157132A (zh) | 一种降低血糖的组合、应用和方法 | |
| Pandit et al. | Obesity context of type 2 diabetes and medication perspectives | |
| US20250195455A1 (en) | Combination nasal and oral therapy for weight loss | |
| CN112437661A (zh) | 苯甲酸或其盐用于预防或治疗抗n-甲基-d-天冬氨酸受体脑炎的用途 | |
| JP6028983B2 (ja) | ビダラビンによる心房細動治療 |